Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tryp Therapeutics Inc (OP: TRYPF ) N/A UNCHANGED Last Price Updated: 3:17 PM EDT, May 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Tryp Therapeutics Inc < Previous 1 2 3 4 5 Next > Tryp Therapeutics and Exopharm Limited Announce Completion of Plan of Arrangement May 01, 2024 Via ACCESSWIRE Tryp Therapeutics Set To Finalize Merger With Exopharm, Announces Trading Halt Ahead Of ASX Listing April 25, 2024 Tryp Therapeutics finalizes merger with Exopharm, prepares for ASX listing with strategic shareholder benefits. Explore merger details now! Via Benzinga BioMedNewsBreaks — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Update on Plan of Arrangement with Exopharm Limited April 24, 2024 Via Investor Brand Network Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt April 24, 2024 Via ACCESSWIRE InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Shareholders Approve Arrangement Agreement at Annual General and Special Meeting March 13, 2024 Via Investor Brand Network Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order March 12, 2024 Via ACCESSWIRE InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Interim Order from BC Supreme Court, Plans Meeting of Securityholders February 09, 2024 Via Investor Brand Network Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting February 08, 2024 Via ACCESSWIRE InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Exopharm Limited Secure Approval from ASX for ‘Pivotal’ Two-Cent Waiver January 26, 2024 Via Investor Brand Network Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX January 26, 2024 Via ACCESSWIRE Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More January 12, 2024 Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD Via Benzinga Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia January 08, 2024 Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milestones. Via Benzinga InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) TRP-8803 Clinical Trial Reaches ‘Significant Milestone’ January 08, 2024 Via Investor Brand Network Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin) January 08, 2024 Via ACCESSWIRE InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Dosing of First Patient in Phase 2a TRP-8802 Clinical Trial January 04, 2024 Via Investor Brand Network Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan January 04, 2024 Via ACCESSWIRE InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Inks Definitive Agreement with Exopharm Limited December 11, 2023 Via Investor Brand Network Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited December 11, 2023 Via ACCESSWIRE InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Closing of Oversubscribed Private Placement November 20, 2023 Via Investor Brand Network Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000 November 20, 2023 Via ACCESSWIRE InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Anticipates Gross Proceeds of AUD$3M on Private Placement November 02, 2023 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Closes on AUD$175,000 Private Placement October 12, 2023 Via Investor Brand Network Exposures Product Safety Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000 October 11, 2023 Via ACCESSWIRE InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Life Sciences Exec as New CEO August 03, 2023 Via Investor Brand Network Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer August 03, 2023 Via ACCESSWIRE InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Reports on the Passing of Director David Tousley August 02, 2023 Via Investor Brand Network With Great Sadness Tryp Announces the Passing of David Tousley, Director August 02, 2023 Via ACCESSWIRE Psyched: NDAA Amendments Blocked, National Practitioners Network, Marijuana In Jackie Kennedy's Garden And More July 19, 2023 GOP-Controlled House Committee Blocks All Cannabis & Psychedelics Amendments To Defense Bill: Now, No Floor Vote Via Benzinga Psilocybin For IBS Gets FDA Nod To Begin Clinical Trials At Mass. General Hospital July 13, 2023 Tryp Therapeutics’ (OTCQB: TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the company to begin Phase 2a clinical trials at the Massachusetts General Hospital... Via Benzinga InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Proceed with Phase 2A Clinical Trial in Patients with IBS July 13, 2023 Via Investor Brand Network < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
